Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).
We report a 19-year-old female with systemic lupus erythematosus and lupus nephritis who developed pulmonary hemorrhage (PH) refractory to conventional immunosuppressive treatment. She was initially treated with intravenous methylprednisolone and cyclophosphamide pulses. She required mechanical ventilation due to a lack of responsiveness and her disease was considered refractory to conventional treatment. Rituximab was administered and this was followed by clinical improvement in both PH and nephritis. Rituximab may be a useful therapeutic option for the treatment of refractory PH.
Pinto
Luis Fernando
LF
Rheumatology Section, Hospital Pablo Tobón Uribe, Medellín, Colombia.
Candia
Liliana
L
Garcia
Patricia
P
Marín
Juan Ignacio
JI
Pachón
Ines
I
Espinoza
Luis R
LR
Marquez
Javier
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006469:Hemoptysis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008181:Lupus Nephritis / Q000150:complications; D000069283:Rituximab; D055815:Young Adult
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab